Tyrosine Kinase Inhibitors: all 10,469 studies that test it

Page 67 of 105. Open to participants first (1,909), then studies with results posted, then the rest; newest registration first within each.

• Clinical Study of PD-1 Monoclonal Antibody SHR-1210 and Apatinib in Advanced NSCLC, Soft Tissue Sarcoma, and Uterine CancerStatus unknownNCT04239443Phase 2
• A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene FusionCompletedNCT04238715Phase 2
• A Study to Evaluate the Safety, Tolerability and Amount of EI-1071 in Blood in Healthy VolunteersCompletedNCT04238364Phase 1
• A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701)Status unknownNCT04234607Phase 3
• Clinical Trial to Assess The Efficacy and Safety of the Combination of Tisagenlecleucel And Ibrutinib in Mantle Cell LymphomaActive, not recruitingNCT04234061Phase 2
• The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I MutationCompletedNCT04233346Phase 2
• Study of Osimertinib in Patients with a Lung Cancer with Brain or Leptomeningeal Metastases with EGFR MutationCompletedNCT04233021Phase 2
• Anlotinib Treatment in Steroid Depenent/Refractory cGVHDTerminatedNCT04232397Phase 2
• Influence of Fedratinib on the Pharmacokinetics of the Transporter Probe Substrates Digoxin, Rosuvastatin, and MetforminCompletedNCT04231435Phase 1
• Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical CancerTerminatedNCT04230954Phase 2
• Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell CarcinomaStatus unknownNCT04229849Phase 2
• A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based ChemotherapyStatus unknownNCT04229615Phase 3
• Safety, Tolerability, Pharmacokinetic Characteristics, and Preliminary Efficacy Evaluation of GST-HG161Status unknownNCT04228406Phase 1
• Efficacy and Safety of Lenvatinib as an Adjuvant Therapy for Hepatocellular CarcinomaStatus unknownNCT04227808Phase 2
• Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLCActive, not recruitingNCT04227028Phase 1
• Clinical Utility of Liquid Biopsy in Brigatinib ALK+ PatientsActive, not recruitingNCT04223596Phase 2
• Study on the Treatment of Soft Tissue Sarcoma With First-line Chemotherapy Failure by Anrotenil Hydrochloride CapsuleCompletedNCT04223583Phase 4
• CM082 in Patients With Myopic Choroidal Neovascularization (CNV)SuspendedNCT04222842Phase 1
• A Study of IBI377 in Combination With Corticosteroids for the Treatment of First-Line Acute Graft-Versus-Host DiseaseTerminatedNCT04220632Phase 1/2
• A Study of Anlotinib in Subjects With Advanced MalignancyCompletedNCT04216082Phase 2
• Anlotinib Combined With TACE in Hepatocellular Carcinoma Patients at High Risk of Post Surgery RecurrenceStatus unknownNCT04213118Phase 2
• Anlotinib Combined With Nivolumab for Non-Small Cell Lung CancerStatus unknownNCT04211896Phase 2
• Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract CancersStatus unknownNCT04211168Phase 2
• A Study of JNJ-64264681 in Participants With Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaCompletedNCT04210219Phase 1
• A Study Comparing the Effects of Famotidine Pretreatment and of Food on the Relative Bioavailability of BMS-986165 in Healthy VolunteersCompletedNCT04209699Phase 1
• Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland CancersActive, not recruitingNCT04209660Phase 2
• A Study To Evaluate The Safety And Efficacy Of PF-06826647 In Participants With Moderate To Severe Ulcerative ColitisWithdrawnNCT04209556Phase 2
• JAK 1/2 Inhibitor, Baricitinib, in the Treatment of Adult IIMCompletedNCT04208464Phase 2
• Perioperative Treatment of Combined SOX With Apatinib and Camrelizumab for Oesophagogastric CancerActive, not recruitingNCT04208347Phase 2/3
• A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III MelanomaActive, not recruitingNCT04207086Phase 2
• D-0316 Versus Icotinib in Patients With Locally Advanced or Metastatic EGFR Sensitising Mutation Positive NSCLCCompletedNCT04206072Phase 2/3
• The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver CancerStatus unknownNCT04204577Phase 2
• A Study of TY-9591 in Advanced Non-small Cell Lung Cancer(NSCLC) Patients With EGFR Positive MutationCompletedNCT04204473Phase 1
• Camrelizumab Combined With Apatinib Mesylate or Camrelizumab Alone for First-line Treatment in Subjects With Programmed Death Ligand 1 (PD-L1) Positive Relapsed or Advanced Non-small Cell Lung Cancer (NSCLC)Status unknownNCT04203485Phase 3
• Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal CancerStatus unknownNCT04202978Phase 1/2
• Cryoablation Combined With Camrelizumab and Apatinib for Multiprimary Lung CancerStatus unknownNCT04201990Phase 1/2
• Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung AdenocarcinomaCompletedNCT04201756Phase 2
• WSD0922-FU for Treatment of Glioblastoma, Anaplastic Astrocytoma, or Non-small Cell Lung Cancer With Central Nervous System MetastasesActive, not recruitingNCT04197934Phase 1
• Hypofractionated Stereotactic Radiotherapy With Anlotinib in Patients With Recurrent High-Grade GliomasActive, not recruitingNCT04197492Phase 2
• Pembrolizumab With Axitinib in Recurrent Endometrial CancerWithdrawnNCT04197219Phase 2
• Camrelizumab Combined with Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric CancerCompletedNCT04195828Phase 2
• Multicentre Placebo-controlled Double-blinded Phase II Study of Lenvatinib Efficacy in Patients With Locally Advanced or Metastatic GIST (Gastrointestinal Stromal Tumor) After Imatinib/Sunitinib FailureCompletedNCT04193553Phase 2
• Anlotinib Combined With Sintilimab as Second-line Treatment or Beyond in Patients With Small Cell Lung CancerStatus unknownNCT04192682Phase 2/3
• Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical StudyStatus unknownNCT04190745Phase 2
• Acalabrutinib for the Treatment of Ibrutinib-Intolerant Mantle Cell LymphomaActive, not recruitingNCT04189757Phase 2
• First-line Chemotherapy for Recurrent Cervical CancerCompletedNCT04188847Phase 2
• Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous LeukemiaCompletedNCT04188405Phase 2
• Study of MAX-40279 in Patients With Relapsed or Refractory Acute Myelogenous Leukemia (AML)Status unknownNCT04187495Phase 1
• A Study in Healthy Male Subjects to Understand How Savolitinib When Taken With Midazolam Behaves Inside the BodyCompletedNCT04187456Phase 1
• Durvalumab (MEDI4736) Plus Cediranib in Patients With Metastatic Uveal MelanomaWithdrawnNCT04184518Phase 2
• MAX-40279-01 in Patients With Advanced Solid TumorsStatus unknownNCT04183764Phase 1
• Camrelizumab, Apatinib and Nab-paclitaxel as Second-line Treatment in Advanced Gastric CancerStatus unknownNCT04182724Phase 1/2
• A Study of Neoadjuvant Chemotherapy Plus Anlotinib in Stage III(N2) Non-small-cell Lung CancerStatus unknownNCT04181372Phase 2
• Study of Neoadjuvant Regimen for Radioactive Iodine Treatment of Metastatic and Advanced Differentiated Thyroid CancersStatus unknownNCT04180007Phase 2
• The Basket Study of Pyrotinib Maleate for HER2-Postive Solid TumorStatus unknownNCT04179656Phase 2
• Phase II Study to Evaluate the Efficacy and Safety of Fruquintinib Plus Sintilimab as Third-line Therapy for Colorectal CancerStatus unknownNCT04179084Phase 2
• A Study in Healthy Male Subjects to Understand How Savolitinib Behaves Inside the Body (Pharmacokinetics) When Administered Alone and in Combination With FamotidineCompletedNCT04179071Phase 1
• Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic LeukemiaCompletedNCT04178798Phase 3
• PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric CancerStatus unknownNCT04174339Not applicable
• Study of the Safety, Tolerability and Pharmacokinetics of HZ-A-018 in Patients With B Cell LymphomaStatus unknownNCT04173455Phase 1
• Cabozantinib With Pemetrexed in Advanced Non-small Cell Lung Cancer, Urothelial Cancer and Malignant MesotheliomaTerminatedNCT04173338Phase 1
• Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue SarcomaCompletedNCT04172805Phase 2
• Study of Zanubrutinib in Japanese Participants With B-Cell MalignanciesCompletedNCT04172246Phase 1/2
• Lenvatinib and Pembrolizumab for the Treatment of Stage IVB Locally Advanced and Unresectable or Stage IVC Metastatic Anaplastic Thyroid CancerActive, not recruitingNCT04171622Phase 2
• Study of Excretion Balance and Pharmacokinetics of [14C]-SAR442168 in Healthy Male SubjectsCompletedNCT04171310Phase 1
• Regorafenib Followed by Nivolumab in Patients With Hepatocellular Carcinoma (GOING)CompletedNCT04170556Phase 1/2
• A Study to Evaluate Long-term Safety of Zanubrutinib Regimens in Participants With B-Cell Malignancies Who Participated in BeiGene Parent Studies of ZanubrutinibActive, not recruitingNCT04170283Phase 3
• Systemic Chemotherapy Plus Lenvatinib and Toripalimab for HCC With Extrahepatic MetastasisStatus unknownNCT04170179Phase 2
• Study of Surufatinib Single Agent or Surufatinib Combined With Toripalimab in Patients With Advanced Solid TumorsCompletedNCT04169672Phase 2
• Lenvatinib Following Liver Transplantation in Patients With High-Risk Hepatocellular CarcinomaStatus unknownNCT04168944Phase 2/3
• Evaluation of AL3818 in Combination With Nivolumab in Solid TumorsActive, not recruitingNCT04165330Phase 1/2
• Efficacy and Safety Study of Anlotinib With Pembrolizumab in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Non-small Cell Lung CancerStatus unknownNCT04164745Phase 2
• Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced MalignanciesCompletedNCT04164199Phase 3
• Dasatinib for the Prevention of Oxaliplatin-Induced Neuropathy in Patients With Metastatic Gastrointestinal Cancer Receiving FOLFOX Chemotherapy With or Without BevacizumabCompletedNCT04164069Phase 1
• Study to Investigate the Absorption, Metabolism, and Excretion of [14C]-BGB-3111 in Healthy MalesCompletedNCT04163783Phase 1
• Study to Evaluate the Effect of Food on the Pharmacokinetics of a BGB-3111 in Healthy SubjectsCompletedNCT04163523Phase 1
• A Study to Evaluate the Efficacy and Safety of Upadacitinib in Participants With Takayasu Arteritis (TAK)Active, not recruitingNCT04161898Phase 3
• The Nintedanib in Progressive Pneumoconiosis Study (NiPPS): a Collaborative NSW Treatment TrialStatus unknownNCT04161014Phase 2
• Study to Evaluate the Reinduction and Second Stop of TKI With Ponatinib in CML in Molecular Response (ResToP)CompletedNCT04160546Phase 2
• A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 AloneStatus unknownNCT04158947Phase 2
• A Study of Azenosertib (ZN-c3) in Participants With Solid TumorsCompletedNCT04158336Phase 1
• Addition of Anlotinib Hydrochloride to the Stupp Regimen Versus the Stupp Regimen Alone for Newly Diagnosed GlioblastomaStatus unknownNCT04157478Phase 2
• Anlotinib In Combination With RFA And TACE in Patients With Middle-advanced HCCStatus unknownNCT04157140Phase 2
• Fruquintinib as Second-line Treatment for Advanced/Metastatic Biliary Tract AdenocarcinomaStatus unknownNCT04156958Phase 2
• Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CPStatus unknownNCT04155411Phase 4
• Effect and Safety of Apatinib on Radiation-Induced Brain InjuryStatus unknownNCT04152681Phase 2
• Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Breast CancerStatus unknownNCT04152057Phase 1/2
• Cabozantinib Plus Nivolumab and Ipilimumab in Women With Recurrent Gynecologic CarcinosarcomaWithdrawnNCT04149275Phase 2
• Osimertinib With or Without Bevacizumab for EGFR- Mutant Non-small Cell Lung Cancer With Leptomeningeal MetastasisStatus unknownNCT04148898Phase 2
• Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3)WithdrawnNCT04148742Phase 1/2
• Stereotactic Radiosurgery Combination With Anlotinib for Limited Brain Metastases With Perilesional Edema in NSCLCStatus unknownNCT04147728Phase 2
• Efficacy and Safety of TKIs' Withdrawal After a Two-step Dose Reduction in Patients with Chronic Myeloid LeukemiaActive, not recruitingNCT04147533Phase 2
• SHR0302 and Steroid As First Line Therapy for Chronic GVHDCompletedNCT04146207Early Phase 1
• A Single-Dose,ComparativeBioavailability Study ofTwo Formulations ofErlotinib150mgTabletsunderFastingConditionsCompletedNCT04145570Phase 4
• ASK120067 Versus Gefitinib as First-line Treatment for EGFRm Locally Advanced or Metastatic NSCLCActive, not recruitingNCT04143607Phase 3
• A Study to Evaluate the Pharmacokinetics and Safety of ASP015K in Healthy Chinese SubjectsCompletedNCT04143477Phase 1
• Tofacitinib in Depression (TIDE)TerminatedNCT04141904Phase 1/2
• Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLCActive, not recruitingNCT04141644Phase 1
• Selinexor as Single Agent and With Imatinib in Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (SeliGIST)Active, not recruitingNCT04138381Phase 1/2
• A Phase I Study to Determine the Effect of Food on the Pharmacokinetic Profile of BPI-7711CompletedNCT04135820Phase 1

← Tyrosine Kinase Inhibitors overview